News for Lobe Sciences Ltd. (LOBE.CN)

Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial s

Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Pri

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial s

Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (”œAlera” or ”œAlera Pharma”), biopharmaceutica

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™ Once issued, this patent will provide additional coverage for psilocin …

VANCOUVER, British Columbia —

U.S. Patent Office issues patent number 12,102,616 Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™ A…

Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.

Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team

Annual General Meeting elects new Board of Directors: Dr. Frederick D. Sancilio, Dr. Harry Jacobson and Mr. Wesley Ramjeet Board announces resignations of CEO Phi…

Wesley Ramjeet to Join Lobe Sciences' Board of Directors, Bringing Decades of Strategic Financial Expertise

VANCOUVER, British Columbia — Lobe Sciences Ltd. (“Lobe” or the “Company”) (OTCQB: LOBEF) (CSE: LOBE), a biopharmaceutical company focused on developing…

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America’s largest...